Enabling Quality-oriented Process Development for sulfidic All-Solid-State Battery Cathodes

After major advances in material research throughout recent years, the industrialization of all-solid-state batteries now depends on the development of cost-effective production technology for novel materials and components. To enable a fast production scale-up and complex process interdependency handling, production engineering needs a quantitative evaluation and comparison approach for manufacturing strategies and process parameter settings. To address this challenge, we derive microstructural quality criteria from specifications at the product-level such as driving range and charging speed of battery electric vehicles. These range from porosity and agglomerate density on a macroscopic level to microscopic properties such as pore size distribution and particle contacts. By listing comprehensive characterization methods, the work enables engineers to efficiently evaluate these criteria. Experimentally applying the proposed approach, the influence of different mixing process parameters is analyzed. Thereby, sulfidic composite cathodes manufactured in a scalable procedure are used as samples

Framework for the Application of Industry 4.0 in Lithium-Ion Battery Cell Production

The application of Industry 4.0 in lithium-ion battery cell production enables companies to achieve increased product quality and global competitiveness, since the majority of value creation takes place in this process. Studies have shown, that improving production performance is the most effective way for battery cell manufacturers to become competitive in the increasingly globalized market. To achieve operational excellence, battery manufacturers must adopt the concepts of networked and digitized production. However, holistically introducing digitalization, data systems and Industry 4.0 methods in all sectors of lithium-ion battery cell production currently poses a major challenge as comprehensive approaches are not available. Therefore, a tailored methodology for the evaluation of suitability and introduction of digitalization and Industry 4.0 is presented. The approach addresses all production-related sectors from logistics to plant engineering to quality management via so called application areas. Multiple development stages divide these into the maturity levels in terms of Industry 4.0. To design each application area and stage, Industry 4.0 use cases from battery cell producers, plant manufacturers, and battery-related research projects are clustered and abstracted for general accessibility. It is shown, that abstracted application areas may be assigned either to all production sectors such as communication or to specific fields such as quality methods. Based on the application areas, corresponding toolboxes are established forming the core of a digitalization guide. To increase the level of maturity with regard to Industry 4.0, the presented paper aims at enabling companies to apply appropriate tools from the toolbox to their production. The systematic and efficient development and implementation of digitalization as well as the holistic assessment of a company's maturity are enabled and provide an essential tool towards increased competitiveness

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial

AIMS: Various beta-blockers with distinct pharmacological profiles are approved in heart failure, yet they remain underused and underdosed. Although potentially of major public health importance, whether one agent is superior in terms of tolerability and optimal dosing has not been investigated. The aim of this study was therefore to compare the tolerability and clinical effects of two proven beta-blockers in elderly patients with heart failure. METHODS AND RESULTS: We performed a double-blind superiority trial of bisoprolol vs. carvedilol in 883 elderly heart failure patients with reduced or preserved left ventricular ejection fraction in 41 European centres. The primary endpoint was tolerability, defined as reaching and maintaining guideline-recommended target doses after 12 weeks treatment. Adverse events and clinical parameters of patient status were secondary endpoints. None of the beta-blockers was superior with regards to tolerability: 24% [95% confidence interval (CI) 20-28] of patients in the bisoprolol arm and 25% (95% CI 21-29) of patients in the carvedilol arm achieved the primary endpoint (P= 0.64). The use of bisoprolol resulted in greater reduction of heart rate (adjusted mean difference 2.1 b.p.m., 95% CI 0.5-3.6, P= 0.008) and more, dose-limiting, bradycardic adverse events (16 vs. 11%; P= 0.02). The use of carvedilol led to a reduction of forced expiratory volume (adjusted mean difference 50 mL, 95% CI 4-95, P= 0.03) and more, non-dose-limiting, pulmonary adverse events (10 vs. 4%; P < 0.001). CONCLUSION: Overall tolerability to target doses was comparable. The pattern of intolerance, however, was different: bradycardia occurred more often in the bisoprolol group, whereas pulmonary adverse events occurred more often in the carvedilol group. This study is registered with controlled-trials.com, number ISRCTN34827306